Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

被引：12

作者：

Ahn, M-J. ^{[1
]}

Lisberg, A. E. ^{[2
]}

Paz-Ares, L. ^{[3
]}

Cornelissen, R. ^{[4
]}

Girard, N. ^{[5
]}

Pons-Tostivint, E. ^{[6
]}

Vicente Baz, D. ^{[7
]}

Sugawara, S. ^{[8
]}

Cobo Dols, M. ^{[9
]}

Perol, M. ^{[10
]}

Mascaux, C. ^{[11
]}

Poddubskaya, E. ^{[12
]}

Kitazono, S. ^{[13
]}

Hayashi, H. ^{[14
]}

Sands, J. ^{[15
]}

Hall, R. ^{[16
]}

Zhang, Y. ^{[17
]}

Zebger-Gong, H. ^{[18
]}

Uema, D. ^{[19
]}

Okamoto, I. ^{[20
]}

机构：

[1] Samsung Med Ctr, Dept Med, Seoul, South Korea

[2] UCLA, Med David Geffen Sch Med, Los Angeles, CA USA

[3] Hosp Univ 12 Octubre, Med Oncol Dept Edificio Maternidad 2a Planta, Madrid, Spain

[4] Erasmus MC, Univ Med Ctr, Pulm Med, Rotterdam, Netherlands

[5] Inst Curie, Thorax Inst, Paris, France

[6] Univ Hosp Nantes, Dept Med Oncol, Nantes, France

[7] Hosp Univ Virgen Macarena, Med Oncol, Seville, Spain

[8] Sendai Kousei Hosp, Pulm Med Dept, Sendai, Miyagi, Japan

[9] Reg & Virgen Victoria Univ Hosp, Med Oncol Interctr Unit, IBIMA, Dept Med Oncol, Malaga, Spain

[10] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[11] Univ Hosp Strasbourg, Dept Pulm, Strasbourg, France

[12] Vitamed LLC, Moscow, Russia

[13] Canc Inst Hosp JFCR, Thorac Med Oncol Dept, Koto Ku, Tokyo, Japan

[14] Kindai Univ, Sch Med Main Campus, Osaka, Japan

[15] Harvard Med Sch, Dana Farber Canc Inst, Thorac Med Oncol, Boston, MA USA

[16] Univ Virginia, Hematooncol Dept, Charlottesville, VA USA

[17] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[18] Dauchi Sankyo Europe GmbH, Global Oncol Clin Dev, Munich, Germany

[19] Daiichi Sankyo USA, Oncol Res & Dev Dept, Parsippany, NJ USA

[20] Kyushu Univ, Dept Resp Med, Fukuoka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.588

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

509MO

引用

页码：S1665 / S1666

页数：2

共 50 条

[31] Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer (BC)
Meric-Bernstam, Funda
Krop, Ian
Juric, Dejan
Kogawa, Takahiro
Hamilton, Erika
Spira, Alexander I.
Mukohara, Toru
Tsunoda, Takuya
Damodaran, Senthil
Greenberg, Jonathan
Gu, Wen
Kobayashi, Fumiaki
Zebger-Gong, Hong
Kawasaki, Yui
Wong, Rie
Bardia, Aditya
CANCER RESEARCH, 2023, 83 (05)
[32] Phase III study of vinflunine versus docetaxel in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum containing regimen
Ramlau, Rodryg
Bennouna, Jaafar
Tan, Eng Huat
Biesma, Bonne
Santoro, Armando
Boni, Corrado
Klein, Helmut
Lesniewski, Krzysztof
Mesia, Ricard
Gatzemeier, Urlich
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S317 - S318
[33] Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02
Levy, Benjamin Philip
Paz-Ares, Luis G.
Su, Wu-Chou
Herbert, Scott M.
Yang, Tsung-Ying
Tolcher, Anthony W.
Lou, Yanyan
Zenke, Yoshitaka
Cortinovis, Diego Luigi
Felip, Enriqueta
Domine, Manuel, Sr.
Leventakos, Konstantinos
Calvo, Emiliano
Horiike, Atsushi
Pan, Edward
Lin, Daisy
Jia, Xiaoyu
Basak, Priyanka
Chisamore, Michael Jon
Goto, Yasushi
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[34] TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer
Oaknin, A.
Meric-Bernstam, F.
Lang, J.
Ciombor, K.
Ray-Coquard, I.
Oza, A.
Yonemori, K.
Xu, R.
Zhao, J.
Gajavelli, S.
Filant, J.
Hovey, T.
Janjigian, Y.
ANNALS OF ONCOLOGY, 2023, 34 : S59 - S60
[35] SYMPTOMS AND IMPACTS IMPORTANT TO PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (ADV/MET NSCLC): RESULTS OF A QUALITATIVE RESEARCH STUDY
Cardellino, A.
Shah, M.
Hanlon, J.
Taiyari, S.
Kelly, K.
de Climens, Roborel
Stojadinovic, A.
VALUE IN HEALTH, 2022, 25 (12) : S431 - S431
[36] Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
Bardia, A.
Jhaveri, K.
Im, S. A.
Simon, S. Pernas
De laurentiis, M.
Wang, S.
Martinez, N.
Borges, G. Santos
Cescon, D. W.
Hattori, M.
Lu, Y. S.
Hamilton, E. P.
Zhang, Q. Y.
Tsurutani, J.
Kalinsky, K.
Xu, L.
Denduluri, N.
Rugo, H. S.
Xu, B.
Pistilli, B.
ANNALS OF ONCOLOGY, 2023, 34 : S1264 - S1265
[37] ECONOMIC BURDEN OF GRADE 3+ADVERSE EVENT MANAGEMENT ASSOCIATED WITH DATO-DXD AND DOCETAXEL-CONTAINING REGIMENS IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER: A EUROPEAN AND USA ANALYSIS
Pfaira, I
Martin, L.
Klint, J.
Galofre, Hopmans G.
Clayson, M.
Le Nouveau, P.
VALUE IN HEALTH, 2024, 27 (12) : S101 - S102
[38] Survival update for the phase III study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC).
Demarinis, F.
Paul, S.
Hanna, N.
Tsao, T. Chang Yao
Adachi, S.
Lim, H. L.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 397S - 397S
[39] Randomized phase II study of gefitinib alone or with simvastatin in previously treated advanced non-small cell lung cancer (NSCLC)
Han, J.
Lee, S.
Yun, T.
Moon, Y.
Park, I.
Kim, H.
Lee, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[40] Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC)
Herbst, Roy S.
Ansari, Rafat H.
Gorbunova, V
Manikhas, G.
Mansoor, N. Boyd
Thomas, E.
Azzoli, Christopher G.
Robert, Francisco
Itri, Loretta M.
Chapman, Robert
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S335 - S335

← 1 2 3 4 5 →